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Abstract
Objective: To assess the impact of the adoption of evidence based guidelines on maternal mortality reduction at Enugu 
State University Teaching Hospital, Nigeria.
Materials and Methods: A retrospective review of all maternal deaths between 1st January, 2005 and 31st December, 
2010 was carried out. Evidence based management guidelines for eclampsia and post-partum hemorrhage were 
adopted. These interventions strategy were carried out from 1st January, 2008-31st December, 2010 and the result 
compared with that before the interventions (2005-2007). Main outcome measure: Maternal mortality ratio (MMR) and 
case fatality rates.
Results: There were 9150 live births and 59 maternal deaths during the study period, giving an MMR of 645/100 000 
live births. Pregnant women who had no antenatal care had almost 10 times higher MMR.
There was 43.5% reduction in the MMR with the interventions (488 vs. 864/100 000 live births P  = 0.039, odds 
ratio = 1.77). There was also significant reduction in case fatality rate for both eclampsia (15.8% vs. 2.7%; P = 0.024, 
odds ratio = 5.84 and Post partum hemorrhage (PPH) (13.6% vs. 2.5% P value = 0.023, odds ratio = 5.5. Obstetric 
hemorrhage was the most common cause of death (23.73%), followed by the eclampsia.
Conclusion: Administration of evidence based intervention is possible in low resource settings and could contribute 
to a significant reduction in the maternal deaths.
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Introduction
As we approach 2015, the target date to achieve the 
Millennium Development Goal 5 (MDG), there has been 
a progressive decline in global annual maternal deaths.[1‑3] 
Maternal deaths have declined globally by almost half from 
543 000 in 1990 to 273 465 in 2011.[1,2]
Maternal mortality ratio (MMR) in developed countries 
has declined significantly to extremely low values of 1.5, 
4.1, 5.3, and 7.9 maternal deaths/100 000 live births in 
Iceland, Ireland, Denmark and Canada respectively.[1] This 
seems not to be the case in developing countries, especially 
in sub‑Saharan Africa with the greatest burden of maternal 
death. MMR still remains one of the key health indicators 
with the widest gap between developed and developing 
countries. MMR is about 12 times higher in developing 
countries.[1,4] Latest MDG report shows that 56% of global 
maternal deaths occurred in sub Saharan Africa, followed 
by 29% in South East Asia.[3]
Nigeria is the most populous nation in sub Saharan Africa 
with a MMR of 525/100 000 live births.[5] Recent report 
indicates that Nigeria is one of the six countries that account 
for 50% of global maternal deaths.[6] There has been global 
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and national initiatives aimed at improving maternal health 
hence reducing the unacceptably high MMR in low income 
countries including Nigeria. In Nigeria, these strategies and 
initiatives include the adoption of the safe motherhood 
initiative launched in Nairobi in 1987, the road map for 
accelerating the attainment of MDG 4 and 5 in 2005, the 
integrated maternal, Newborn, and child health strategy in 
2007 and currently the establishment of the midwife service 
scheme to address the shortage of skill birth attendants at 
delivery. Despite all these policies and strategies, maternal 
death still remains a great challenge in Nigeria.
In Nigeria, the 5 leading causes of maternal death include 
obstetric hemorrhage, eclampsia, sepsis, obstructed labor 
and complications of unsafe abortion.[7‑10] Some of deaths 
from these causes are preventable.
A previous study at Enugu State University Teaching 
Hospital (ESUTH), reported an unacceptably high MMR 
of 840/100 000 live births and identified eclampsia and 
obstetric hemorrhage, (especially post‑partum hemorrhage) 
as the two most common causes of maternal death.[8] Based 
on this earlier report, the Department of Obstetrics and 
Gynecology adopted evidence based strategies toward 
addressing these two major causes of maternal death in 
the institution with the aim of reducing maternal deaths.
The study aims at evaluating the impact of the adoption 
of this evidence based guidelines on maternal mortality 
reduction in the institution. Maternal and perinatal 




ESUTH is a tertiary health institution located in Enugu, 
a metropolitan city and the capital of Enugu State, South 
East, and Nigeria. It provides health services to about seven 
million people of Enugu State and other neighboring states 
of Ebonyi, Anambra, Imo, Abia, and some parts of Benue 
State. It is the only government owned tertiary hospital 
within the city center offering obstetric services.
Study design
A retrospective review of all maternal deaths at ESUTH 
over a period of 6 year; 3 years before (1st January, 
2005‑31st December, 2007) and after (1st January, 
2008‑31st December, 2010) the adoption of the guidelines 
aimed at maternal mortality reduction. The case files of all 
maternal deaths were retrieved (91% retrieval rate) from 
the medical records department and relevant data including 
the age, parity, marital, booking, and educational status of 
women and the cause of deaths were extracted for analysis. 
Additional supplementary data were extracted also from 
the admission and discharge register, delivery (labor ward) 
register, operation (theatre) register, and hospital death 
register.
According to the World Health Organization, maternal 
death is defined “death of a woman while pregnant or within 
42 days of termination of pregnancy, irrespective of the 
duration and site of the pregnancy, from any cause related 
to or aggravated by the pregnancy or its management, but 
not from accidental or incidental causes.”[12]
Maternal deaths before arrival at the hospital were excluded 
from the study. Furthermore, maternal deaths due to 
accidental and incidental causes were excluded from the 
study.
Post‑mortem examination was not carried out in any 
case recorded as the relations of the deceased refused the 
procedure.
Intervention
The department identified eclampsia and post‑partum 
hemorrhage as the two most common causes of maternal 
deaths. Evidence based management options and guidelines 
were identified through literature review in PubMed and 
Google scholar. These guidelines were adapted to our local 
setting and were presented at departmental academic 
board meeting. It was approved by the departmental board. 
There was training and retraining of all resident doctors 
and nurses in the department on these guidelines.The final 
adopted guidelines included: (1) The use of magnesium 
sulfate (MgSO4) for the management of severe preeclampsia 
and eclampsia using the pritchard regimen. Pritchard 
regimen involves the administration of a loading dose of 4 g 
of MgSO4 intravenously over a period not less than 5 min 
followed immediately by deep intramuscular injection of 
5 g in each buttock. Subsequently a maintenance dose of 
5 g administered intramuscularly every 4 hourly in alternate 
buttock.[13] This maintenance dose is continued for 24 h after 
the last episode of convulsion or delivery. Prior to this time, 
diazepam was the drug used for the management of eclampsia 
in the hospital; (2) Active management of the third stage 
of all labor with intramuscular oxytocin 10 IU giving within 
1 min of delivery of the infant. In a patient with risk factor for 
PPH, it was augmented with either oxytocin infusion 20 IU 
in 500 ml of ringer’s lactate over 4 h or 0.5 mg ergometrine 
intramuscularly. Ergometrine was avoided in hypertensive 
and cardiac disease patients. Although oxytocin and 
ergometrine were used previously in the institution, there was 
no outlined guideline. Secondly, active management of the 
third stage of all labor was not the case in the institution then.
Clinical parameters such as the presence of knee jerk 
reflex, respiratory rate > 15 cycles/min and urine output 
> 25 ml/min were used to monitor patients on magnesium 
sulfate treatment as illustrated by Tukur.[14]
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Study variables
These measures were implemented for a period of 
3 years (1st January 2008‑31st December 2010) hence the 
need to assess its impact by comparing with the previous 
years (1st January 2005‑31st December, 2007) using MMR 
and case fatality rate as outcome measures.
Statistical analysis
The results were analyzed using the Statistical Package for 
Social Science (SPSS) version 17 using Fisher’s exact test 
and Chi‑square (with Yates correction) as appropriate at 
95% confidence interval. P value (two tailed) less than 0.05 
was considered statistically significant. Ethical approval was 
obtained from the ethical committee of the hospital.
Results
There were 9150 live births and 59 maternal deaths within 
the 6 years study period giving a MMR of 645/100 000 
live births [Table 1]. Majority of the women belonged 
to age group 30‑39 years, were parity 0‑4 (74.6%), were 
married (89.2%) and were “unbooked,” i.e. women who 
had no antenatal care (57.6%). Forty seven (80.2%) women 
had completed secondary education. The mean age of the 
women was 31.4 ± 5.6 years.
MMR was almost 10 times higher among those that had no 
antenatal care (3096/100 000 vs. 310/100 000 live births, 
Chi‑squared with Yates correction = 109; P < 0.001. Odds 
ratio = 9.97).
There was 43.5% reduction in the MMR with the adoption 
of the interventions (488 vs. 864/100 000 live births, 
P = 0.039, odds ratio = 1.77) Table 2.
There was over 80% reduction in the case fatality rate for 
eclampsia (15.8% vs. 2.7%; P = 0.024, odds ratio = 5.84). 
The case fatality rate for PPH also dropped by 82% (13.6% 
vs. 2.5% P = 0.023, odds ratio = 5.5). There was about 30% 
decline in prevalence of PPH (2.17% vs. 1.50%, P value 
0.007, odds ratio 1.5) Table 3.
Obstetric hemorrhage was the most common cause 
of maternal death (23.73%), mainly post‑partum 
hemorrhage (84.5%) followed by eclampsia. Human 
immunodeficiency virus infection/acquired immune 
deficiency syndrome contributed 9.2% of maternal 
deaths [Table 4].
Discussion
The MMR over the 6 year period was 645/100 000 live 
births. This value is lesser than 840/100 000 live births 
reported earlier in the institution.[8] It is also lower than 
1098 and 903/100 000 live births reported in similar tertiary 
health institutions in Nnewi and Ebonyi respectively in 
the same South Eastern region of Nigeria.[9,15] Although, 
this may be a sign of improvement in maternal care in the 
institution, the MMR is still very high, almost 36 times 
higher than the average MMR of 18/100 000 live births in 
the developed world.[1] MMR is one of the key indices for 
measuring the state of maternal health in a region. These 
findings buttress the huge gap in the quality of care between 
the developing and developed countries.
Women who had no antenatal care during the pregnancy 
had MMR almost 10 times higher than those that had 
antenatal care. Antenatal care has been shown as one 
Table 3: The prevalence rate and case fatality rate distribution for Eclampsia and PPH during the study period
Year No. of deaths No. of cases No. of deliveries Prevalence rate (PR %) P value CFR P value
Eclampsia
2005-2007 9 57 4049 1.41 N/A 15.8 0.024
2008-2010 2 74 5649 1.31 0.0072 2.7
PPH
2005-2007 12 88 4049 2.17 13.6 0.023
2008-2010 2 80 5649 1.42 2.5
PPH=Post partum hemorrhage, PR=Prevalence rate, CFR=Case fatality rate
Table 2: Maternal mortality ratio distribution before 




No. of maternal 
deaths
No. of live 
births
MMR
2005-2007 33 3820 864
2008-2010 26 5330 488
59 9150 645
χ2=4.288; 95% CI, P value=0.038, Odds ratio=1.77, MMR=Maternal 
mortality ratio
Table 1: Yearly maternal mortality ratio distribution
Year No. of maternal 
deaths




2005 10 1172 853
2006 12 1222 981
2007 11 1426 771
2008 10 2116 473
2009 8 1986 402
2010 8 1228 651
Total 59 9150 645
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of the interventions that can reduce maternal mortality 
as it provides an opportunity to offer intervention and 
information to pregnant women that will promote good 
health and survival of mother and the babies. World 
Health Organization recommends a minimum of four 
visits.[3] In Nigeria, 36% of pregnant women do not 
receive antenatal care[5] and this may be contributory to 
the high national MMR. Universal access to prenatal care 
to all pregnant women is very necessary in our effort to 
achieve MDG 5.
There was 43.5% reduction in MMR with the adoption 
of these interventions in the department. The use of 
magnesium sulfate with clear guidelines for management of 
eclampsia might have been associated with this reduction. 
There was also a significant reduction in the case fatality rate 
for eclampsia with the introduction of Magnesium sulfate in 
the department. Similar findings has recently been reported 
in Kano, in Northern Nigeria.[16,17] Magnesium sulfate is the 
drug of choice for prevention of both initial seizure[18] as well 
as recurrence of seizures.[19,20] Both randomized control trials 
as well as real world use of magnesium sulfate has shown a 
significant decline, almost a 50% drop in maternal death 
when compared to diazepam, or phenytoin and even lytic 
cocktail.[21] Before the routine use of magnesium sulfate 
in the UK for the treatment of eclampsia, 7 deaths were 
recorded among 383 eclamptic women,[22] but none recorded 
after its introduction in 214 eclamptic women.[23] Although, 
the role of MgS04 in reduction of maternal death from 
eclampsia is well‑established, its use remains low in many 
low resource countries like Nigeria due to the challenges of 
its availability at all times and cost barrier.[14] MgS04 should 
be made freely available in our health institutions. There 
should be training and retraining of health care providers on 
how it can be administered safely and monitored for toxicity. 
These should be complimented with a clear guideline on its 
use displayed at strategic positions.
Active management of all labor cases in this study may 
have also contributed to the reduction of MMR during the 
intervention period. There was a significant reduction in the 
prevalence of post‑partum hemorrhage as well as the case 
fatality rate during the period. The clearly written guidelines 
available for the care providers at the labor ward and post 
natal ward might have helped promote promptness in action 
thus, eliminating unnecessary delays. Hemorrhage, mostly 
post‑partum hemorrhage constitutes about 30% (in some 
countries 50%) of direct maternal death worldwide.[11] It 
contributed 23.7% in our study. It has been observed that 
achieving the MDG 5 by 2015 is unattainable except priority 
attention is paid towards its prevention and treatment 
especially in low resource countries.[11,24]
International federation of gynecology and obstetrics, in 
pursuant of this objective recently published a safe, effective 
and feasible guideline for the prevention and treatment 
of post‑partum hemorrhage in low resource settings with 
a recommendation for its adoption by health institutions 
offering maternity care. This involves active management 
of the third stage of all labor with oxytocics.[24]
The study is a retrospective pre/post intervention study with 
the challenge of incomplete data and quality of documented 
information. To overcome these challenges, all record in the 
various units and department were checked and relevant 
data extracted.
In conclusion, evidence‑based intervention with clear 
guidelines can be successfully implemented in low resource 
countries and could contribute significantly in the reduction 
of maternal deaths associated with post‑partum hemorrhage 
and eclampsia.
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